Author:
Bickel Angelika,Koneth Irene,Enzler-Tschudy Annette,Neuweiler Jörg,Flatz Lukas,Früh Martin
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference4 articles.
1. Alley EW, Schellens JHM, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). J Thor Oncol. 2015;10(suppl2), ORAL11.03.
2. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18.
3. Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89(3):720.
4. Schroeter NJ, Rushing DA, Parker JP, Baltos E. Minimal-change nephrotic syndrome associated with malignant mesothelioma. Arch Intern Med. 1986;146(9):1834–6.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献